Platelets play a key role in the pathogenesis of acute coronary syndromes and this is why antiplatelet drugs are essential, both in the acute phase and in the long-term follow-up in preventing recurrent myocardial infarction, stroke and cardiovascular death. Aspirin is the most used agent and still remains the first choice drug for lifelong administration in secondary prevention after myocardial infarction. Dual antiplatelet therapy, targeting more than one pathway of platelet activation, has significantly improved the outcome of patients with acute coronary syndromes despite an increased risk of bleeding complications. The aim of this article is to provide an overview of the evidence from randomized clinical trials with a focus on the best association between aspirin and a P2Y 12 inhibitor such as clopidogrel, prasugrel or ticagrelor, on the selection of the appropriate agent based on the revascularization strategy and on the optimal duration of such an intensive treatment. We will also provide the latest evidence regarding new antithrombotic agents, such as vorapaxar or low dose rivaroxaban, that could be associated with dual antiplatelet therapy in high risk patients with the aim of further reducing the rate of major ischaemic complications. Finally we will address the issue of patients presenting with atrial fibrillation and a concomitant acute coronary syndrome who frequently need a percutaneous coronary intervention, with a specific focus on the combination therapy of antiplatelet and anticoagulant agents and on the current recommendations of the guidelines.
Introduction
Both platelets and the coagulation cascade are involved in the thrombus formation process. If a thrombus is superimposed over a disrupted atherosclerotic plaque, platelet involvement is prevalent, while thrombin activation (at the end of the coagulation cascade) is responsible both for further platelet activation and aggregation and for fibrin formation, thus stabilizing the thrombus structure. This platelet-rich thrombus, which is macroscopically white, usually occurs in the arterial bed. 1 On the other hand, when the thrombotic process occurs in the vein bed, where it is triggered by stasis and inflammation, the coagulation cascade is much more involved than platelets: the final thrombus, macroscopically red, will be formed mainly by fibrin with platelets entrapped in it. 2 This is the main reason why antiplatelet treatment has a key role in atherothrombotic diseases such as myocardial infarction and stroke, while anticoagulants are much more indicated in the prevention of cardioembolic stroke and systemic embolism complicating atrial fibrillation. The combination of antiplatelet and anticoagulant agents is indicated in different clinical settings: some examples are the acute phase of an acute coronary syndrome (parenteral anticoagulants in combination with antiplatelets) or the long-term treatment of patients with atrial fibrillation who undergo percutaneous coronary interventions (PCIs). Combination of antithrombotic agents increases the risk of major bleeding compared with one single agent, thus suggesting that the proper balance between bleeding and ischaemic risk in any individual patient should be the main driver of any therapeutic choice. Indeed, in randomized clinical trials, patients at high bleeding risk have been frequently identified by older age, known anaemia, history of haemorrhagic events, predisposing haematologic disorders or the need for a combined treatment with antiplatelets and anticoagulants 3 and these variables have been included in most of the bleeding risk scores that have been proposed for the everyday practice.
In this review we critically discuss the role of antiplatelet and anticoagulant agents in secondary prevention after myocardial infarction; we will also address their potential combinations in several clinical settings with a special focus on recent advances.
Aspirin and dual antiplatelet treatment Single antiplatelet therapy
In patients with stable coronary artery disease, long-term single antiplatelet therapy (SAPT) with aspirin reduces the risk of new cardiovascular events by approximately 20-25% compared with placebo. 4, 5 Lifelong SAPT with aspirin is therefore recommended as secondary prevention, both in stable coronary artery disease and in stabilized patients >12 months after an acute coronary syndrome (ACS). [6] [7] [8] Acetylsalicylic acid acts via irreversible inhibition of platelet cyclo-oxygenase-1, which is normally complete with chronic dosing 75 mg/day. Contrary to the antiplatelet effects, the gastrointestinal side effects of aspirin increase at higher doses. The optimal risk-benefit ratio appears to be achieved with an aspirin dosage of 75-100 mg/day. Clopidogrel (75 mg daily) is an alternative antiplatelet agent in patients with aspirin intolerance. 9 Clopidogrel (300-600 mg loading and 75 mg/day maintenance dose) is a prodrug that requires oxidation by the hepatic cytochrome P450 (CYP) system to generate an active metabolite, which selectively and irreversibly inactivates platelet P2Y 12 receptors and thus inhibits adenosine diphosphateinduced platelet aggregation. There is consistent evidence demonstrating that SAPT withdrawal in coronary symptomatic patients is harmful, increasing the risk of stent thrombosis and myocardial infarction (MI). 10 
Dual antiplatelet therapy: aspirin and clopidogrel
Targeting more than one pathway of platelet activation leads to additive antithrombotic effects, and such dual antiplatelet therapy (DAPT) has proven to be an effective strategy in individuals at higher risk of arterial thrombosis. Unfortunately, targeting more than one pathway also leads to more bleeding. The CURE study showed that in patients with ACS, DAPT with aspirin and clopidogrel, compared with aspirin alone, reduced the rate of the composite endpoint of MI, stroke or cardiovascular death by 20% (9.3% vs. 11.4%; relative risk (RR) 0.80, 95% confidence interval (CI) 0.72-0.90; p < 0.001), but increased the risk of major bleeding (3.7% vs. 2.7%; RR 1.38, 95% CI 1.13-1.67; p < 0.001). 11, 12 This regimen is currently the recommended DAPT strategy for patients undergoing elective PCI for stable coronary artery disease, and for ACS patients at high risk of bleeding such as the ones who require oral anticoagulant therapy in addition to DAPT. 8, 13 The recommended duration of DAPT after elective PCI depends on the stent type, the bleeding risk and the ischaemic risk ( Table 1) .
The interindividual variability in response to clopidogrel has long been recognized as a limitation of this drug; it is partly related to the inherited variability of the CYP 2C19 activity 14, 15 but also to non-genetic factors such as age, disease states and drug interactions. 16, 17 This variability combined with the slower onset of action has led to the displacement of clopidogrel by other P2Y 12 inhibitors in patients with ACS.
Aspirin and prasugrel
Prasugrel is a prodrug that irreversibly blocks P2Y 12 platelet receptors with a faster onset and a more potent antiplatelet inhibition than clopidogrel due to more efficient generation of its active metabolite. 18 In ACS patients planned for PCI, the combination of aspirin and prasugrel reduced the risk of recurrent cardiovascular events by 18% compared with the combination of aspirin and clopidogrel, but increased the risk of major bleeding by 32%. 19 However, excluding patients with a high bleeding risk, prasugrel offers significant benefit over clopidogrel without substantially increasing major bleeding, and the combination of aspirin and prasugrel is currently recommended in preference to aspirin and clopidogrel in STEMI patients planned for primary PCI, or ACS patients without ST-elevation planned for PCI once coronary anatomy is known. 7, 8 Prasugrel compared with clopidogrel did not significantly reduce ischaemic events in ACS patients who were medically managed 20 and is not recommended in this setting. Pre-treatment of ACS patients with a prasugrel loading dose before coronary angiography is not recommended after a recent trial demonstrated an increase in bleeding complications with no benefit. 21 Prasugrel is contraindicated in patients with a prior haemorrhagic or ischaemic stroke/transient ischaemic attack (TIA) due to evidence 12 inhibitor administration in addition to aspirin beyond one year may be considered after careful assessment of the ischaemic and bleeding risks of the patient 8
IIb A a Class I: evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective; Class II: conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure; Class IIb: usefulness is less well established by evidence/ opinion. b Level of evidence A: data derived from multiple randomized clinical trials or meta-analyses; Level of evidence B: data derived from a single randomized clinical trial or large non-randomizedtudies; Level of evidence C: consensus of opinion of the experts and/or small studies, retrospective studies, registries. ESC: European Society of Cardiology; SCAD: stable coronary artery disease; DAPT: dual antiplatelet therapy; BMS: bare-metal stent; DES: drug-eluting stent of net harm, and should also be avoided in patients over the age of 75 years and/or with a body weight < 60 kg. 7, 8 Aspirin and ticagrelor
Ticagrelor is an oral, reversibly binding P2Y 12 inhibitor with a more rapid and consistent onset of action compared with clopidogrel as well as a faster offset of action. In the PLATO trial, the combination of aspirin and ticagrelor reduced the risk of major adverse cardiovascular events compared with DAPT with aspirin and clopidogrel in the first year after ACS (9.8% vs. 11.7%: hazard ratio 0.84, 95% CI: 0.77-0.92; p < 0.001). 22 Again, the risk of non coronary artery bypass graft-related major bleeding was increased. The combination of aspirin and ticagrelor is currently recommended as first-line therapy in patients with ACS without ST-elevation regardless of management strategy, and in STEMI patients undergoing primary PCI. 7, 8 Ticagrelor is contraindicated in patients with prior history of intracranial haemorrhage. Dyspnoea is a common adverse effect, usually occurring early during treatment, and is usually well tolerated although sometimes necessitates switching to another P2Y 12 inhibitor. 23, 24 Due to the increased risk of bleeding, neither prasugrel nor ticagrelor are recommended in patients who require oral anticoagulant therapy. 13 
Long-term DAPT
Patients who have experienced an ACS are at high risk of recurrences both in the year after the first episode and beyond. Moreover most of them undergo PCI with stent implantation in the acute phase and might be at risk of stent thrombosis if not adequately protected by the appropriate antithrombotic therapy. Long-term follow-up of some national cohorts of patients included into the GRACE study has shown a persistent high risk of cardiovascular death, MI, stroke and re-hospitalization for ACSs at five years, despite high rates of guidelines indicated therapies. Patients with non-STelevation MI as index event were more prone to developing ischaemic complications compared with patients with ST-elevation MI (STEMI), thus presenting a higher burden of morbidity and late-mortality. 25 While a single antiplatelet regimen, more often based on aspirin, is considered standard of care for all patients with a coronary artery disease as life-long secondary prevention strategy, the optimal duration of dual antiplatelet treatment is still a matter of debate. A first trial of long-term DAPT with aspirin and clopidogrel versus aspirin alone in a broad population of patients with risk factors or prior atherothrombotic diseases did not show a statistically significant benefit of DAPT. Despite this negative result, a post-hoc analysis documented a reduction of ischaemic events at longterm follow-up in those patients with a prior MI, thus suggesting the opportunity to select only this population for future clinical trials testing the same hypothesis. 26 More than five years later the Dual AntiPlatelet Therapy study, a randomized, placebo-controlled clinical trial, enrolled patients who previously had been PCI treated with the implantation of a stent (mainly a drug-eluting one) and had completed the first year of follow-up without ischaemic or bleeding events while on DAPT with aspirin and a thienopyridine drug. Patients were randomized to stop clopidogrel or prasugrel and remain on aspirin alone or to continue with the two drugs for other 18 months, with the aim of determining benefits and risk of a prolonged DAPT. 27 Acute MI was the reason for revascularization in 26% of the overall population of the trial. Patients treated with long-term DAPT showed a lower rate of stent thrombosis and of major cardiac and cerebrovascular adverse events compared with patients receiving placebo; in patients on prolonged DAPT the study also demonstrated a significant increase of the rate of moderate or severe bleeding and of all-cause mortality. In patients with acute MI at presentation or with a history of prior MI, prolonged DAPT was associated with a similar mortality rate compared with placebo, thus resulting in a net clinical benefit of the long-term approach in this subpopulation. 28 More recently, the randomized, double-blind, placebo-controlled PEGASUS-TIMI 54 trial was designed to assess whether two different doses of ticagrelor, 90 mg twice daily and 60 mg twice daily, on a background of aspirin therapy could reduce ischaemic events compared with aspirin alone in patients with a history of prior MI 1-3 years before randomization. 29 Each of the two ticagrelor doses was better than aspirin in preventing the composite of cardiovascular death, MI or stroke during a median follow-up time of 33 months, with a trend for ticagrelor towards the reduction of cardiovascular death. Both doses of ticagrelor were associated with an increase of major bleeding complications, but no differences in intracranial haemorrhages or fatal bleeds have been reported among the three arms of randomization. 30 Both doses of ticagrelor consistently reduced the risk of ischaemic events in predefined subgroups, including patients with diabetes, chronic kidney disease or peripheral artery disease, [31] [32] [33] as well as patients with recent discontinuation of P2Y 12 therapy regardless of the time of index MI, suggesting a strategy of uninterrupted P2Y 12 inhibition with ticagrelor 34 in these high risk subjects. A dose of ticagrelor of 60 mg twice daily should be preferred because it was as effective as 90 mg twice daily while associated with numerically lower major and minor bleeding complications.
Finally, in a systematic review and meta-analysis of randomized clinical trials including both DAPT and PEGASUS-TIMI 54 studies, a total of 33,435 patients with prior MI receiving long-term DAPT have been evaluated with respect to the occurrence of cardiovascular death, recurrent MI or stroke over a mean follow-up of 31 months. DAPT beyond one year was associated with a lower risk of ischaemic events and a higher rate of major bleeding complications compared with aspirin alone, with no significant differences in total mortality and fatal bleeding. 35 On the basis of these results, the European Society of Cardiology (ESC, 2015) guidelines for the management of ACS in patients presenting without persistent ST-segment elevation, suggest that a P2Y 12 inhibitor on top of aspirin beyond one year might be considered in patients at high risk of ischaemic events, after a careful evaluation of the risk of bleeding complications (Class IIb, level of evidence A). 8 
Oral inhibitors of the protease-activated receptor 1 and of factor Xa for secondary prevention after a MI
The presence of distinct pathways in coagulation and platelet activation has provided the rationale for combined pharmacotherapy in patients with acute and chronic atherothrombosis. Two classes of antithrombotic drugs that have been investigated in recent years as long-term options include oral inhibitors of the protease-activated receptor (PAR)-1 and of factor Xa.
Thrombin, the key protease of the coagulation cascade, is also a very potent platelet agonist. Thrombinmediated platelet activation occurs through PAR-1 and PAR-4 receptors, with the former acting as the principal thrombin receptor. 36 Vorapaxar, the first-in-class PAR-1 inhibitor, has been investigated in a large, placebo-controlled phase III programme. This included a trial in 12,944 patients with high risk ACS without ST-elevation (TRACER) 37 and a parallel study in 26,449 patients with history of MI, ischaemic stroke or peripheral arterial disease (TRA 2P). 38 After an unplanned safety review, the data and safety monitoring board recommended the termination of study medication in patients with a history of stroke enrolled in the TRA 2P trial, owing to the increased risk of intracranial haemorrhage, and the early termination of the TRACER trial, being in the follow-up phase.
The TRACER trial compared vorapaxar (with a loading dose of 40 mg followed by a daily dose of 2.5 mg) with matching placebo. The primary endpoint, a composite of cardiovascular death, MI, stroke, recurrent ischaemia with rehospitalization, or urgent coronary revascularization, was not significantly reduced by vorapaxar (hazard ratio 0.92, 95% CI 0.85-1.01; p ¼ 0.07) but a nominal reduction of cardiovascular death, MI or stroke was observed (hazard ratio 0.89, 95% CI 0.81-0.98; p ¼ 0.02) driven by an effect on MI (hazard ratio 0.88; 95% CI 0.79-0.98; p ¼ 0.021). Moderate or severe bleeding was increased by vorapaxar (hazard ratio 1.35, 95% CI 1.16-1.58; p < 0.001), including intracranial haemorrhage (hazard ratio 3.39, 95% CI, 1.78-6.45; p < 0.001).
In the TRA 2P trial, patients with stable atherothrombosis (previous MI, stroke or peripheral artery disease (PAD)) were randomized to vorapaxar 2.5 mg daily or matching placebo and followed for a median of 30 months. At three years, the primary composite end point of cardiovascular death, MI or stroke was lower in the vorapaxar group (hazard ratio 0.87, 95% CI 0.80-0.94; p < 0.001). Similar to TRACER, moderate or severe bleeding was increased in patients randomized to vorapaxar (hazard ratio 1.66, 95% CI 1.43-1.93; p < 0.001), including intracranial haemorrhage (1.0%, vs. 0.5% in the placebo group; p < 0.001). In the subgroup of patients < 75 years, with no history of TIA or stroke, and bodyweight >60 kg (n ¼ 14,909, 84% of previous MI population), there was a substantial effect of vorapaxar on cardiovascular death, MI or stroke (hazard ratio 0.75, 95% CI 0.66-0.85; p < 0.0001) with an increase of GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) moderate (hazard ratio 1.84, 95% CI 1.35-2.51; p ¼ 0.001) but not of GUSTO severe bleeding (hazard ratio 1.13, 95% CI 0.77-1.64; p ¼ 0.53). 39 Notably, the proportion of patients receiving concomitant clopidogrel was 87.4% in TRACER and 78.1% of those who qualified because of previous MI in TRA 2P.
On the basis of these studies, vorapaxar in addition to aspirin and/or clopidogrel has been approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the reduction of thrombotic cardiovascular events in patients with a history of MI or with PAD, while it is contraindicated in patients with a prior stroke or TIA.
Rivaroxaban, the first oral factor Xa inhibitor, competitively and selectively inhibits factor Xa and it does not require cofactors (such as antithrombin) to exert its anticoagulant effect. As adjunctive therapy in patients with a recent ACS, rivaroxaban was tested in the ATLAS ACS 2-TIMI 51 trial. 40 Patients with a history of stroke or TIA were excluded. In this study, 15,526 patients with a recent ACS were randomized in a 1:1:1 ratio to receive twice-daily doses of 2.5 mg or 5 mg rivaroxaban or matching placebo for a mean of 13 months. Rivaroxaban significantly reduced the primary end point of cardiovascular death, MI, or stroke as compared with placebo (HR for the rivaroxaban group, 0.84; 95% CIs, 0.74 to 0.96; P ¼ 0.008). The twice-daily 2.5-mg dose of rivaroxaban also reduced the rates of all cause death (2.9% vs. 4.5%, P ¼ 0.002), a survival benefit that was not seen with the twice-daily 5 mg dose. As compared with placebo, rivaroxaban substantially increased the rates of major bleeding not related to coronary artery bypass grafting (2.1% vs. 0.6%, P < 0.001) and of intracranial haemorrhage (0.6% vs. 0.2%, P ¼ 0.009). Overall, 92.9% of patients enrolled in the ATLAS ACS 2-TIMI 51 study received concomitant clopidogrel therapy ( Table 2) .
The FDA rejected the use of rivaroxaban for ACS in May 2012, after extensive review, while the drug was approved by the EMA. Currently, rivaroxaban 2.5 mg twice daily is considered by the ESC guideline (Class IIb, level of evidence B) in highly selected patients with no prior stroke/TIA, who are at high ischaemic risk as well as low bleeding risk while receiving aspirin and clopidogrel. 8 In conclusion, the role of vorapaxar 2.5 mg daily and rivaroxaban 2.5 mg twice daily for secondary prevention after MI is very limited. They are contraindicated in patients with a history of any cerebrovascular accident and have not yet been studied in patients receiving concomitant therapy with potent P2Y 12 inhibitors, including ticagrelor. Therefore the use of either vorapaxar or rivaroxaban might thus be considered in patients receiving aspirin and/or clopidogrel if the risk of recurrent thrombotic events is high and the bleeding risk is low.
Antiplatelet treatment in patients who need anticoagulation for non-valvular atrial fibrillation
Non-valvular atrial fibrillation is defined as atrial fibrillation that occurs in the absence of mechanical prosthetic heart valves and in the absence of moderate to severe mitral stenosis. 40, 41 This arrhythmia is common in patients with coronary artery disease (CAD), both in ACS and in patients with chronic stable angina.
In the ACS setting, atrial fibrillation has been reported in 2.3-21% of hospitalized patients. The prognostic impact of atrial fibrillation occurring in ACS is still controversial: some studies describe an independent negative impact on mortality (especially in patients with concomitant cardiogenic shock) while others fail to demonstrate such an association. 41 In stable CAD the arrhythmia is present in 4-5% of patients and has been associated with a worse clinical outcome. 42 Moreover, atrial fibrillation is associated with a twofold increase of the risk of MI and half of patients with new onset atrial fibrillation have an underlying CAD. 41, 42 Atrial fibrillation could be associated with an increased risk of embolic stroke that warrants oral anticoagulation (OAC), according to established risk scores. 42, 43 The risk of stroke has to be balanced against the risk of bleeding, especially in patients with concomitant CAD who are treated with antiplatelet agents and coronary stents. OAC plus aspirin and clopidogrel increases the relative risk of bleeding by 79-134% compared with single or dual antiplatelet treatment. 42 The optimal combination antithrombotic therapy and its duration for atrial fibrillation patients with CAD whether or not undergoing PCI are still a matter of debate and represent a clinical challenge.
Combination antithrombotic therapy in ACS/PCI patients with atrial fibrillation
Recent ESC guidelines 42 and expert consensus 43 suggest that atrial fibrillation patients at risk for stroke should continue OAC during and after stenting and after an episode of ACS. In general, a short period of triple therapy (OAC, aspirin, clopidogrel) is recommended, followed by a period of dual therapy (OAC plus a single antiplatelet), the combination and duration being based on a careful assessment of thrombotic and bleeding risk (Figure 1) .
When choosing antiplatelet agents for dual or triple therapy, aspirin is a mainstay, while clopidogrel is the preferred P2Y 12 inhibitor. Current guidelines recommend the use of clopidogrel over other thienopyridine drugs, due to the lack of evidence for the latter and for safety reasons: clopidogrel is in fact associated with a lower risk of major bleeding.
Currently, the use of prasugrel or ticagrelor in the context of triple therapy should be avoided unless there is a clear need for these drugs (e.g. stent thrombosis on aspirin plus clopidogrel). Ongoing trials will provide more data about such combination therapy in the future.
The omission of aspirin while maintaining clopidogrel and OAC has been evaluated in the WOEST trial, in which 573 anticoagulated patients undergoing PCI (70% with atrial fibrillation) were randomized to either dual therapy with warfarin and clopidogrel or to triple therapy with warfarin, clopidogrel and aspirin. 44 Bleeding was lower in the dual versus triple therapy arm (mainly driven by fewer minor bleedings). The rates of ischaemic endpoints did not differ, but all-cause mortality was lower in the dual therapy group at one year (2.5% vs. 6.4%). More recently the ISAR-TRIPLE trial evaluated the optimal duration of triple therapy after PCI in an overall population of 614 patients receiving a drug-eluting stent. The study did not show any significant difference in either ischaemic or bleeding complications when six weeks of clopidogrel were compared with six months in the context of triple therapy. 45 Both these studies were small and not powered to look at ischaemic endpoints, and the recent ESC guidelines still recommend a period of triple therapy for all patients.
When a novel OAC is used in this setting, the lowest dose effective for stroke prevention should be considered. Dose reduction below the approved dosing tested in phase III trials for stroke prevention in atrial fibrillation is not recommended. 41 AF patient in need of OAC after an ACS A very recent randomized controlled study, the PIONEER AF-PCI trial, investigated the safety of anticoagulation with rivaroxaban at two different doses plus one or two antiplatelet agents in patients undergoing PCI. The patients were randomized to low-dose rivaroxaban (15 mg once daily) plus a P2Y 12 inhibitor for 12 months (group 1), very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for one, six or 12 months (group 2), or standard therapy with a doseadjusted vitamin K antagonist (once daily) plus DAPT for one, six or 12 months (group 3). The study showed a significant lower incidence of the primary safety outcome of clinically significant bleeding in groups 1 and 2 compared with group 3. The rates of ischaemic events were similar in the three groups, but with broad CIs, and the study was not powered to look at ischaemic events. 46 Larger clinical trials are currently ongoing to test other direct OACs in combination with DAPT in this population.
Long-term combination antithrombotic therapy in ACS/PCI patients with atrial fibrillation
In stabilized patients with atrial fibrillation one to six months after an ACS, current European guidelines recommend DAPT with aspirin or clopidogrel plus OAC. 41 Guidelines suggest selecting the time of triple versus dual therapy on the basis of the bleeding risk profile of any individual patient. Guidelines also suggest administering lifelong OAC as single therapy, without antiplatelet drugs, after one year in all patients, even though randomized controlled trials adequately powered to demonstrate a true net clinical benefit of this strategy are actually lacking (Figure 1) . Such a recommendation is based on data from registries and meta-analysis of small studies, which have shown that in stable CAD patients with concomitant atrial fibrillation warfarin alone is safe and effective compared with warfarin plus aspirin. 47 More clinical trials are therefore needed to define the optimal antithrombotic regimen in patients with ACS and atrial fibrillation, including further investigations into the potential role of direct OACs in combination with the newer antiplatelet agents.
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